Compare Biogen Inc (BIIB) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Waste Management, Inc. — how do they compare? Biogen Inc trades at $195.45 (market cap $28.34B), while Waste Management, Inc. trades at $234.64 (market cap $94.08B). The key difference: Waste Management, Inc. is far larger — about 3.3× Biogen Inc's market cap, and Waste Management, Inc. pays a 1.51% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WM | |
|---|---|---|
Market Cap | $28.34B | $94.08B |
Sector | Health | Industrials |
52-Week High | $216.63 | $246.51 |
52-Week Low | $122.68 | $196.77 |
Enterprise Value | $30.62B | $116.81B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
WM trades at $236.71, up 1.45% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages and a consensus analyst price target of $263.57. Recent earnings beat expectations in Q1 2026, with revenue growth to $25.20 billion in 2025. The company maintains solid profitability with a 10.99% net margin and offers a dividend, with the next payment scheduled for June 18, 2026.
Outlook remains positive due to pricing discipline and renewable energy initiatives, but high valuation multiples (P/E 34.26) and recent earnings misses pose risks. Institutional sentiment is bullish with no sell ratings, though debt levels have increased. Key near-term catalyst is Q2 2026 earnings release on July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
